688506 百利天恒
盘后交易 10-26 15:00:00
资讯
新帖
简况
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
证券之星 · 01:17
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
百利天恒最新公告：T-BrenIII期临床试验达主要终点
证券之星 · 10-25 16:31
百利天恒最新公告：T-BrenIII期临床试验达主要终点
百利天恒最新公告：双抗ADC新药上市申请获受理
证券之星 · 10-25 16:29
百利天恒最新公告：双抗ADC新药上市申请获受理
10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股
证券之星 · 10-23 16:42
10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股
百利天恒涨5.73%，开源证券一个月前给出“买入”评级
证券之星 · 10-23 16:42
百利天恒涨5.73%，开源证券一个月前给出“买入”评级
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
证券之星 · 10-23
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》
百利天恒：宜泽康®治疗HR+HER2-乳腺癌药品上市申请获受理
格隆汇 · 10-22
百利天恒：宜泽康®治疗HR+HER2-乳腺癌药品上市申请获受理
10月20日百利天恒涨6.40%，中欧医药生物混合发起A基金重仓该股
证券之星 · 10-20
10月20日百利天恒涨6.40%，中欧医药生物混合发起A基金重仓该股
百利天恒涨6.40%，开源证券一个月前给出“买入”评级
证券之星 · 10-20
百利天恒涨6.40%，开源证券一个月前给出“买入”评级
百利天恒（688506）披露2026年度第一期科技创新债券发行结果，10月15日股价上涨2.07%
证券之星 · 10-15
百利天恒（688506）披露2026年度第一期科技创新债券发行结果，10月15日股价上涨2.07%
大健康“A+H”退潮，谁还能上桌？
蓝鲸财经 · 10-15
大健康“A+H”退潮，谁还能上桌？
百利天恒（688506）披露宜泽康®纳入优先审评程序公告，10月13日股价下跌0.61%
证券之星 · 10-13
百利天恒（688506）披露宜泽康®纳入优先审评程序公告，10月13日股价下跌0.61%
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准通知书的公告》
证券之星 · 10-13
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准通知书的公告》
百利天恒最新公告：宜泽康®新适应症纳入优先审评程序
证券之星 · 10-12
百利天恒最新公告：宜泽康®新适应症纳入优先审评程序
百利天恒最新公告：宜泽康®联合放疗治疗头颈鳞癌获临床试验批准
证券之星 · 10-11
百利天恒最新公告：宜泽康®联合放疗治疗头颈鳞癌获临床试验批准
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于聘任证券事务代表的公告》
证券之星 · 10-08
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于聘任证券事务代表的公告》
百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单
智通财经 · 09-27
百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单
百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书
证券之星 · 09-27
百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书
百利天恒最新公告：宜泽康®纳入突破性治疗品种名单
证券之星 · 09-27
百利天恒最新公告：宜泽康®纳入突破性治疗品种名单
百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%
证券之星 · 09-24
百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":253.5,"timestamp":1792998000000,"preClose":267.5,"halted":0,"volume":2331088,"delay":0,"changeRate":-0.0523,"floatShares":413000000,"shares":413000000,"eps":-3.8096,"marketStatus":"盘后交易","change":-14,"latestTime":"10-26 15:00:00","open":266,"high":272,"low":252,"amount":610000000,"amplitude":0.0748,"askPrice":253.5,"askSize":11,"bidPrice":253.2,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-3.8096,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793064600000},"marketStatusCode":4,"adr":0,"adjPreClose":267.5,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792978200000,1792985400000],[1792990800000,1792998000000]],"highLimit":294.25,"lowLimit":240.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":22.7,"roa":"--","roe":"--","epsLYR":-2.61,"committee":-0.070423,"marketValue":104664000000,"turnoverRate":0.0056,"status":1,"afterMarket":{"amount":50700,"volume":200,"close":253.5,"buyVolume":732,"sellVolume":0,"time":1792999086746,"indexStatus":"盘后交易 10-26 15:18:06","preClose":267.5},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1792999088089,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":104664000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2678135272","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678135272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678135272?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:17","pubTimestamp":1792948628,"startTime":"0","endTime":"0","summary":"治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告四川百利天恒药业股份有限公司自主研发的宜泽康治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性HR+HER2-乳腺癌的药品上市申请已获国家药品监督管理局药品审评中心受理。目前该药物已有2项适应症获批上市，另有2项适应症上市申请已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678187687","title":"百利天恒最新公告：T-BrenIII期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2678187687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678187687?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:31","pubTimestamp":1792917072,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)在经曲妥珠单抗和紫杉烷类治疗失败的不可切除局部晚期或转移性HER2阳性乳腺癌III期临床试验中，经独立数据监查委员会判断，预设期中分析达到无进展生存期主要终点。该药正在国内外开展21项临床试验，其中2项适应症已被国家药监局药品审评中心纳入突破性治疗品种名单。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678503187","title":"百利天恒最新公告：双抗ADC新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2678503187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678503187?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:29","pubTimestamp":1792916986,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创双抗ADC药物“伦康依隆妥单抗”用于治疗EGFR-TKI耐药EGFR突变非小细胞肺癌的药品上市申请获国家药监局药审中心正式受理。该药为全球首个且唯一获批上市的EGFR×HER3双抗ADC，此次受理基于III期临床试验期中分析结果，已达到无进展生存期主要终点。截至目前，该药已有2项适应症获批上市，2项适应症上市申请获受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677944916","title":"10月23日百利天恒涨5.73%，中欧医药生物混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677944916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677944916?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:42","pubTimestamp":1792744933,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日百利天恒涨5.73%，收盘报267.5元，换手率0.54%，成交量2.21万手，成交额5.72亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中欧基金的中欧医药生物混合发起A。中欧医药生物混合发起A目前规模为0.22亿元，最新净值1.0036，较上一交易日下跌4.02%。中欧医药生物混合发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","163118","000808.SH","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677494494","title":"百利天恒涨5.73%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677494494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677494494?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:42","pubTimestamp":1792744923,"startTime":"0","endTime":"0","summary":"今日百利天恒涨5.73%，收盘报267.5元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","161027","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677199883","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）治疗局部晚期、复发或转移性HR+HER2-乳腺癌的药品上市申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677199883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677199883?lang=zh_cn&edition=full","pubTime":"2026-10-23 01:31","pubTimestamp":1792690269,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，百利天恒报收于253.0元，上涨0.36%，换手率0.44%，成交量1.83万手，成交额4.63亿元。公司公告汇总：百利天恒自主研发的宜泽康治疗HR+HER2-乳腺癌的药品上市申请获国家药监局药审中心受理，基于III期临床试验期中分析达无进展生存期主要终点。宜泽康为全球首个EGFR×HER3双抗ADC，已在多种肿瘤类型中开展超45项临床试验，多项适应症获突破性治疗认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300001866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677957093","title":"百利天恒：宜泽康®治疗HR+HER2-乳腺癌药品上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2677957093","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677957093?lang=zh_cn&edition=full","pubTime":"2026-10-22 19:31","pubTimestamp":1792668688,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665559","title":"10月20日百利天恒涨6.40%，中欧医药生物混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665559?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:29","pubTimestamp":1792484943,"startTime":"0","endTime":"0","summary":"证券之星消息，10月20日百利天恒涨6.40%，收盘报253.23元，换手率0.56%，成交量2.3万手，成交额5.7亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中欧基金的中欧医药生物混合发起A。中欧医药生物混合发起A目前规模为0.14亿元，最新净值1.0298，较上一交易日上涨0.79%。中欧医药生物混合发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000024479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","000808.SH","163118","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676658086","title":"百利天恒涨6.40%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2676658086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676658086?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:28","pubTimestamp":1792484928,"startTime":"0","endTime":"0","summary":"今日百利天恒涨6.40%，收盘报253.23元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000024475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675743533","title":"百利天恒（688506）披露2026年度第一期科技创新债券发行结果，10月15日股价上涨2.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675743533","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675743533?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:38","pubTimestamp":1792075093,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘，百利天恒报收于231.17元，较前一交易日上涨2.07%，最新总市值为954.44亿元。近日，四川百利天恒药业股份有限公司发布《关于2026年度第一期科技创新债券发行结果的公告》。公告显示，公司2026年度第一期科技创新债券已完成发行，实际发行总额10亿元，发行利率1.90%，期限为5+5年，起息日为2026年10月15日，兑付日为2036年10月15日。募集资金已于2026年10月15日到账。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500039811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675619300","title":"大健康“A+H”退潮，谁还能上桌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675619300","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675619300?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:16","pubTimestamp":1792055774,"startTime":"0","endTime":"0","summary":"2026年以来，A股大健康上市公司的赴港上市明显降温。可以说，港股终止上市也没有与该风波有直接关联。该企业负债率约25%，因此市场猜测“A+H”上市的诉求并非缺钱续命，而是全球化战略布局。头部医疗器械、创新药龙头持续坚守“A+H”双平台战略，持续获得机构认可，港股上市成为全球化发展的配套工具。归根结底，大健康板块的“A+H”上市潮退是行情、规则、企业基本面三重因素叠加的结果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792043506360832246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE0008368742.USD","LU0084288322.USD","VXUS","LU2348773727.SGD","LU1979443071.USD","LU2488822045.USD","LU1064131003.USD","IE00B031HY20.USD","LU0594300419.USD","LU2148510915.USD","IE00B29SXG58.USD","LU0359202008.SGD","BK4588","LU1146622755.USD","688266","LU1997245094.SGD","LU0572944931.SGD","KCAI","LU2348774022.SGD","LU1934453819.USD","LU1688375341.USD","LU2424517915.HKD","LU1064130708.USD","LU0594300179.USD","LU1781817850.SGD","IPOS","300760","BK4585","IE0031814852.USD","LU0650527681.SGD","BK0251","BK0229","IE00B031J352.USD","LU0823426480.USD","LU0823426308.USD","LU2213484517.USD","LU0327786744.USD","SGXZ49509284.SGD","LU1655091616.SGD","LU0605514214.HKD","688506","IE0005HP3H50.USD","LU1734074674.USD","688639","688166","SGXZ81163826.USD","LU1820825898.SGD","LU0359201612.USD","LU0405327148.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675337902","title":"百利天恒（688506）披露宜泽康®纳入优先审评程序公告，10月13日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675337902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675337902?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:21","pubTimestamp":1791883303,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，百利天恒报收于226.6元，较前一交易日下跌0.61%，最新总市值为935.57亿元。近日，四川百利天恒药业股份有限公司发布自愿披露公告，称其自主研发的宜泽康治疗EGFR-TKI耐药的EGFR突变的局部晚期或转移性非鳞状非小细胞肺癌被国家药品监督管理局药品审评中心纳入优先审评品种名单。此次纳入符合“纳入突破性治疗药物程序的药品”优先审评范围。截至目前，宜泽康已有3项适应症被纳入CDE优先审评品种名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300028643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675735801","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675735801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675735801?lang=zh_cn&edition=full","pubTime":"2026-10-13 00:59","pubTimestamp":1791824350,"startTime":"0","endTime":"0","summary":"公司公告汇总四川百利天恒药业股份有限公司自愿披露关于宜泽康联合放疗治疗局部晚期不可切除头颈鳞癌及其他实体瘤获得药物临床试验批准通知书的公告四川百利天恒药业股份有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意其自主研发的全球首创EGFR×HER3双抗ADC宜泽康联合放疗开展用于治疗局部晚期不可切除头颈鳞癌及其他实体瘤的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674987760","title":"百利天恒最新公告：宜泽康®新适应症纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2674987760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674987760?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:00","pubTimestamp":1791806455,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创EGFR×HER3双抗ADC宜泽康(伦康依隆妥单抗)被国家药监局药品审评中心纳入优先审评品种名单，拟定适应症为经EGFR-TKI治疗失败的EGFR敏感突变的局部晚期或转移性非鳞状非小细胞肺癌。截至目前，宜泽康已有3项适应症被纳入优先审评品种名单，9项适应症被纳入突破性治疗品种名单。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200030993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674181463","title":"百利天恒最新公告：宜泽康®联合放疗治疗头颈鳞癌获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2674181463","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674181463?lang=zh_cn&edition=full","pubTime":"2026-10-11 15:50","pubTimestamp":1791705002,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药监局批准签发的《药物临床试验批准通知书》，公司自主研发的全球首创双抗ADC药物宜泽康(伦康依隆妥单抗)联合放疗局部晚期不可切除头颈鳞癌及其他实体瘤的临床试验获批准。截至目前，该药已在中国和美国开展超45项临床试验，其中III期临床研究20项，已有9项适应症被CDE纳入突破性治疗品种名单。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101100001976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014975","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司关于聘任证券事务代表的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673014975?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:17","pubTimestamp":1791393427,"startTime":"0","endTime":"0","summary":"公司公告汇总四川百利天恒药业股份有限公司关于聘任证券事务代表的公告公司于2026年9月29日召开第五届董事会第十一次会议，聘任郑婷女士为证券事务代表，协助董事会秘书履行职责，任期自董事会审议通过之日起至第五届董事会任期届满之日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670405636","title":"百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405636","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405636?lang=zh_cn&edition=full","pubTime":"2026-09-27 19:31","pubTimestamp":1790508687,"startTime":"0","endTime":"0","summary":"除此次新纳入外，2025年11月，T-Bren用于既往经一线抗HER2治疗及一线标准化疗方案治疗失败的HER2阳性局部晚期或转移性胃癌或胃食管结合部腺癌患者方案已被药审中心纳入突破性治疗品种名单并完成公示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670033444","title":"百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2670033444","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670033444?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:41","pubTimestamp":1790498483,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，自主研发的创新生物药注射用BL-M12D1(ADC)的临床试验获得批准，同意本品单药开展在复发性或难治性血液系统恶性肿瘤的临床试验。该药品是与宜泽康(伦康依隆妥单抗，BL-B01D1/iza-bren)共享同一“连接子+毒素”平台的ADC药物。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670345403","title":"百利天恒最新公告：宜泽康®纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2670345403","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670345403?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:41","pubTimestamp":1790498460,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的宜泽康(伦康依隆妥单抗，BL-B01D1/iza-bren)用于既往经含铂化疗治疗失败的复发性或转移性胆道癌患者方案，已被国家药监局药审中心纳入突破性治疗品种名单，近日已完成公示。截至目前，宜泽康已有9项适应症被纳入突破性治疗品种名单，1项适应症获美国FDA突破性疗法认定。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669466040","title":"百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669466040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669466040?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242590,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，百利天恒报收于239.3元，较前一交易日下跌3.62%，最新总市值为988.01亿元。公司于近日披露《关于提前归还临时补充流动资金的募集资金的公告》。公告显示，四川百利天恒药业股份有限公司于2025年9月29日召开董事会，同意使用不超过7亿元闲置募集资金暂时补充流动资金，期限自董事会批准日起不超过12个月，该资金用于创新药研发及主营业务相关生产经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792999088366,"stockEarnings":[{"period":"1week","weight":0.1437},{"period":"1month","weight":0.0774},{"period":"3month","weight":-0.1399},{"period":"6month","weight":-0.0582},{"period":"1year","weight":-0.2383},{"period":"ytd","weight":-0.1721}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9075人(较上一季度增加16.69%)","perCapita":"45495股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}